Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer-BioNTech COVID-19 vaccine was 91% effective in 5- to 11-year-olds in Phase 3 study

By Brian Buntz | October 22, 2021

Pfizer-BioNTechPfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) have announced that their COVID-19 vaccine was 90.7% effective at protecting against symptomatic COVID-19 in children ages 5 to 11. 

The study concluded that a 10-µg dose of the BNT162b2 vaccine, which is one-third the amount authorized for people 12 and older, had the best benefit-risk profile.

Recipients of 20- and 30-µg doses had significantly higher rates of mild or moderate side effects, including fatigue, headache, chills and muscle pain. 

The independent Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet next week to discuss the prospect of recommending the vaccine for use in 5- to 11-year-olds to the FDA. 

 The BNT162b2 vaccine is currently FDA approved for people 16 and older. An emergency use authorization currently covers children aged 12 to 15.

One concern regarding the use of the vaccine in younger children is its association with myocarditis and pericarditis in a small number of recipients. Myocarditis is inflammation involving heart muscle, while pericarditis involves inflammation of heart lining. The VRBPAC meeting session will include a presentation on the risk of myocarditis in adolescents and young adults from Dr. Mathew Oster, a pediatric cardiologist at Children’s Healthcare in Atlanta. 

Pfizer reported no cases of myocarditis or pericarditis approximately three months after administering the second dose in the children between the ages of 5 and 11.  

The study found no new safety signals linked to the drug and reported that adverse events were in line with other trials. 

The number of children infected with COVID-19 skyrocketed with the spread of the Delta variant as students returned to school, jumping 419% in August and September compared with the prior two months, according to a Pfizer briefing document shared with FDA. 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?
Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50